Nkarta (NKTX) Accounts Payables (2019 - 2026)
Nkarta (NKTX) posted quarterly Accounts Payables of $1.6 million for Q1 2026, up 6.44% year-over-year from $1.5 million in Q1 2025, and down 24.08% quarter-over-quarter from $2.1 million in Q4 2025.
Nkarta (NKTX) Accounts Payables (2019 - 2026) Analysis & Trends
Nkarta's Accounts Payables history runs 8 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 6.44% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 6.44% YoY), while the FY2025 annual figure was $2.1 million, up 227.43% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.6 million, down from $2.1 million in the prior quarter.
- The five-year high for Accounts Payables was $9.5 million in Q3 2022, with the low at $638000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $2.1 million (2025), against an average of $3.0 million.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 343.85% in 2022, then slumped 82.59% in 2024.
- Nkarta's Accounts Payables stood at $1.8 million in 2022, then surged by 108.12% to $3.7 million in 2023, then plunged by 82.59% to $638000.0 in 2024, then jumped by 227.43% to $2.1 million in 2025, then retreated by 24.08% to $1.6 million in 2026.
- Business Quant data shows NKTX's Accounts Payables at $1.6 million in Q1 2026, $2.1 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.82 Mn |
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 4.28 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 9.49 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | 2.02 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 2.14 Mn |